首页 中华实验眼科杂志 2024年42卷08期 DR患者眼内液细胞因子变化及其意义
中华实验眼科杂志
期刊首页
过刊列表
高级检索
稿件发表
• 综述 •
ENGLISH ABSTRACT
DR患者眼内液细胞因子变化及其意义
米雪景 
谷潇雅
[综述]
[综述]
喻晓兵 
[综述]
[综述]
作者及单位信息
·
DOI： 10.3760/cma.j.cn115989-20201106-00752
Changes and significance of cytokines in the intraocular fluids in patients with diabetic retinopathy
Mi Xuejing
Gu Xiaoya
Yu Xiaobing
Authors Info & Affiliations
Mi Xuejing
Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China
Gu Xiaoya
Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China
Yu Xiaobing
Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China
·
DOI： 10.3760/cma.j.cn115989-20201106-00752
376
93
0
0
2
0
扫描转手机阅读
下载中华医学期刊APP阅读更流畅 体验更丰富
PDF下载
APP内阅读
摘要
糖尿病视网膜病变(DR)是与持续高血糖相关的一种慢性、进行性、潜在危害视力的视网膜微血管疾病，若不能得到及时有效治疗，将严重损害视力，给患者生活带来极大不便。DR的发生和发展涉及血－视网膜屏障损害、炎症、神经退行性变等多种机制。房水和玻璃体液能直接反映眼球内环境的改变，对眼内病变的进展有很好的提示作用。近年来，眼内液中多种细胞因子在DR发病过程中的变化、对病程进展的影响及治疗后的改变已得到广泛关注。本文将针对DR患者眼内液中多种血管生成相关细胞因子，如血管内皮生长因子、胎盘生长因子、半乳糖凝集素1、血管紧张素1(Ang1)、Ang2及炎症相关细胞因子，如肿瘤坏死因子α、细胞间黏附分子1、血管内皮细胞黏附分子1、单核细胞趋化蛋白1、转化生长因子β、白细胞介素(IL)-1β、IL-6、IL-8、IL-10的变化、糖尿病黄斑水肿和增生性DR治疗前后细胞因子的变化及其意义进行综述，为探寻DR新的、个性化的临床治疗方案提供潜在靶点，为改善DR患者的预后提供理论依据。
糖尿病视网膜病变;细胞因子;房水;玻璃体液;个性化治疗;综述
ABSTRACT
Diabetic Retinopathy (DR) is a chronic, progressive and potentially harmful retinal microvascular disease that is associated with persistent hyperglycemia.Without timely and effective treatment, it will seriously damage the vision of patients and bring great inconvenience to their lives.The development of DR involves various mechanisms such as blood-retinal barrier damage, inflammation and neurodegeneration.Intraocular fluids, including aqueous humor and vitreous fluid, can directly reflect the changes in the intraocular environment and have a good indication of the progress of intraocular lesions.In recent years, the changes of various cytokines in intraocular fluid during the occurrence of DR and their influence on the disease course and their changes after treatment have been widely studied.This article focuses on the changes in angiogenesis-related cytokines such as vascular endothelial growth factor, placental growth factor, galectin-1, angiotensin 1 (Ang1), Ang2 and inflammation-related cytokines such as tumor necrosis factor-α, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, monocyte chemoattractant protein-1, transforming growth factor-β, interleukin (IL)-1β, IL-6, IL-8, IL-10 in the intraocular fluid of DR patients, and the changes of these cytokines and the significance after treatment in patients with diabetic macular edema and proliferative DR to provide potential targets for exploring new and personalized clinical treatment and theoretical basis to improve the prognosis of patients with DR.
Diabetic retinopathy;Cytokines;Aqueous humor;Vitreous fluid;Personalized treatment;Review
Yu Xiaobing, Email:
mocdef.aabnisgniboaixuy
Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文
米雪景,谷潇雅,喻晓兵. DR患者眼内液细胞因子变化及其意义[J]. 中华实验眼科杂志,2024,42(08)：750-757.
DOI:10.3760/cma.j.cn115989-20201106-00752PERMISSIONS
Request permissions for this article from CCC.
评价本文
*以上评分为匿名评价
本文评分
0分
[累计0个]
向我们报错
版权归中华医学会所有。
未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。
除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。
糖尿病视网膜病变(diabetic retinopathy，DR)是糖尿病常见的微血管并发症，按病变严重程度可分为非增生性糖尿病视网膜病变(non proliferative diabetic retinopathy，NPDR)和增生性糖尿病视网膜病变(proliferative diabetic retinopathy，PDR)。糖尿病黄斑水肿(diabetic macular edema，DME)是DR患者视力受损的重要原因，严重影响患者正常的工作和生活。为保留患者视力，提高患者生活质量，重度NPDR、PDR及DME的及时有效治疗非常重要。目前，对重度NPDR、PDR和DME的治疗方法主要包括抗血管内皮生长因子(vascular endothelial growth factor，VEGF)、糖皮质激素、激光光凝、手术等，但均存在一定局限
[
1
]。寻找更多的治疗靶点在控制DR进展、提高患者预后方面具有重要意义。眼内液中细胞因子水平能够直观反映眼内环境的改变，不仅对DR的进展和治疗效果有提示作用，而且可用于开展DR患者的个性化治疗。本文将对DR患者眼内液中，包括DME和PDR治疗前后细胞因子的变化进行综述，为DR的临床治疗提供理论依据。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
已是订阅账户?
登录
参考文献
[1]
Cai S ， Bressler NM . Aflibercept，bevacizumab or ranibizumab for diabetic macular oedema：recent clinically relevant findings from DRCR.net Protocol T[J]. Curr Opin Ophthalmol， 2017，28(6)∶636－643. DOI：
10.1097/ICU.0000000000000424
.
[2]
Urias EA ， Urias GA ， Monickaraj F ，et al. Novel therapeutic targets in diabetic macular edema：beyond VEGF[J]. Vision Res， 2017，139∶221－227. DOI：
10.1016/j.visres.2017.06.015
.
[3]
Wang W ， Lo A ．Diabetic retinopathy：pathophysiology and treatments[J/OL]. Int J Mol Sci， 2018，19(6)∶1816[2024－01－20]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032159/. DOI：
10.3390/ijms19061816
.
[4]
Whitehead M ， Wickremasinghe S ， Osborne A ，et al. Diabetic retinopathy：a complex pathophysiology requiring novel therapeutic strategies[J]. Expert Opin Biol Ther， 2018，18(12)∶1257－1270. DOI：
10.1080/14712598.2018.1545836
.
[5]
Simó R ， Hernández C ．Neurodegeneration in the diabetic eye：new insights and therapeutic perspectives[J]. Trends Endocrinol Metab， 2014，25(1)∶23－33. DOI：
10.1016/j.tem.2013.09.005
.
[6]
Holmes DI ， Zachary I ．The vascular endothelial growth factor (VEGF) family：angiogenic factors in health and disease[J/OL]. Genome Biol， 2005，6(2)∶209[2024－01－20]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC551528/. DOI：
10.1186/gb-2005-6-2-209
.
[7]
Funatsu H ， Yamashita H ， Noma H ，et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients[J]. Graefes Arch Clin Exp Ophthalmol， 2005，243(1)∶3－8. DOI：
10.1007/s00417-004-0950-7
.
[8]
Wu J ， Zhong Y ， Yue S ，et al. Aqueous humor mediator and cytokine aberrations in diabetic retinopathy and diabetic macular edema：a systematic review and meta-analysis[J/OL]. Dis Markers， 2019，2019∶6928524[2024－01－20]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906842/. DOI：
10.1155/2019/6928524
.
[9]
Murakami T ， Frey T ， Lin C ，et al. Protein kinase cβ phosphorylates occludin regulating tight junction trafficking in vascular endothelial growth factor-induced permeability
in vivo
[J]. Diabetes， 2012，61(6)∶1573－1583. DOI：
10.2337/db11-1367
.
[10]
Zhang X ， Wu J ， Wu C ，et al. Comparison of aqueous humor levels of PlGF and VEGF in proliferative diabetic retinopathy before and after intravitreal conbercept injection[J/OL]. Diabetes Res Clin Pract， 2020，162∶108083[2024－01－20]. https://pubmed.ncbi.nlm.nih.gov/32057965/. DOI：
10.1016/j.diabres.2020.108083
.
[11]
Paine SK ， Mondal LK ， Borah PK ，et al. Pro- and antiangiogenic VEGF and its receptor status for the severity of diabetic retinopathy[J]. Mol Vis， 2017，23∶356－363.
[12]
Al Kahtani E ， Xu Z ， Al Rashaed S ，et al. Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment[J]. Eye (Lond)， 2017，31(4)∶529－536. DOI：
10.1038/eye.2016.246
.
[13]
Ando R ， Noda K ， Namba S ，et al. Aqueous humour levels of placental growth factor in diabetic retinopathy[J/OL]. Acta Ophthalmol， 2014，92(3)∶e245－246[2024－01－20]. https://pubmed.ncbi.nlm.nih.gov/23910830/. DOI：
10.1111/aos.12251
.
[14]
Tsai T ， Kuehn S ， Tsiampalis N ，et al. Anti-inflammatory cytokine and angiogenic factors levels in vitreous samples of diabetic retinopathy patients[J/OL]. PLoS One， 2018，13(3)∶e0194603[2024－01－20]. https://pubmed.ncbi.nlm.nih.gov/29584759/. DOI：
10.1371/journal.pone.0194603
.
[15]
Zhao B ， Cai J ， Boulton M ．Expression of placenta growth factor is regulated by both VEGF and hyperglycaemia via VEGFR-2[J]. Microvasc Res， 2004，68(3)∶239－246. DOI：
10.1016/j.mvr.2004.07.004
.
[16]
Jiao W ， Ji JF ， Xu W ，et al. Distinct downstream signaling and the roles of VEGF and PlGF in high glucose-mediated injuries of human retinal endothelial cells in culture[J/OL]. Sci Rep， 2019，9(1)∶15339[2024－01－21]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814860/. DOI：
10.1038/s41598-019-51603-0
.
[17]
Nguyen QD ， De Falco S ， Behar-Cohen F ，et al. Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases[J/OL]. Acta Ophthalmol， 2018，96(1)∶e1－e9[2024－01－21]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811779/. DOI：
10.1111/aos.13325
.
[18]
Wells JA ， Glassman AR ， Ayala AR ，et al. Aflibercept，bevacizumab，or ranibizumab for diabetic macular edema：two-year results from a comparative effectiveness randomized clinical trial[J]. Ophthalmology， 2016，123(6)∶1351－1359. DOI：
10.1016/j.ophtha.2016.02.022
.
[19]
Yang N ， Zhang W ， He T ，et al. Silencing of galectin-1 inhibits retinal neovascularization and ameliorates retinal hypoxia in a murine model of oxygen-induced ischemic retinopathy[J]. Exp Eye Res， 2017，159∶1－15. DOI：
10.1016/j.exer.2017.02.015
.
[20]
Kanda A ， Dong Y ， Noda K ，et al. Advanced glycation endproducts link inflammatory cues to upregulation of galectin-1 in diabetic retinopathy[J/OL]. Sci Rep， 2017，7(1)∶16168[2024－01－21]. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29170525/. DOI：
10.1038/s41598-017-16499-8
.
[21]
Kanda A ， Noda K ， Saito W ，et al. Aflibercept traps galectin-1，an angiogenic factor associated with diabetic retinopathy[J/OL]. Sci Rep， 2015，5∶17946[2024－01－21]. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/26648523/. DOI：
10.1038/srep17946
.
[22]
Ridano ME ， Subirada PV ， Paz MC ，et al. Galectin-1 expression imprints a neurovascular phenotype in proliferative retinopathies and delineates responses to anti-VEGF[J/OL]. Oncotarget， 2017，8(20)∶32505－32522[2024－01－21]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464805/. DOI：
10.18632/oncotarget.17129
.
[23]
Abu El-Asrar AM ， Ahmad A ， Allegaert E ，et al. Galectin-1 studies in proliferative diabetic retinopathy[J/OL]. Acta Ophthalmol， 2020，98(1)∶e1－e12[2024－01－21]. https://pubmed.ncbi.nlm.nih.gov/31318490/. DOI：
10.1111/aos.14191
.
[24]
Saharinen P ， Eklund L ， Alitalo K ．Therapeutic targeting of the angiopoietin-TIE pathway[J]. Nat Rev Drug Discov， 2017，16(9)∶635－661. DOI：
10.1038/nrd.2016.278
.
[25]
Khalaf N ， Helmy H ， Labib H ，et al. Role of angiopoietins and tie-2 in diabetic retinopathy[J]. Electron Physician， 2017，9(8)∶5031－5035. DOI：
10.19082/5031
.
[26]
Tayyari F ， Khuu LA ， Sivak JM ，et al. Retinal blood oxygen saturation and aqueous humour biomarkers in early diabetic retinopathy[J/OL]. Acta Ophthalmol， 2019，97(5)∶e673－e679[2024－01－22]. https://pubmed.ncbi.nlm.nih.gov/30690929/. DOI：
10.1111/aos.14016
.
[27]
Klaassen I ， de Vries EW ， Vogels I ，et al. Identification of proteins associated with clinical and pathological features of proliferative diabetic retinopathy in vitreous and fibrovascular membranes[J/OL]. PLoS One， 2017，12(11)∶e0187304[2024－01－22]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667868/. DOI：
10.1371/journal.pone.0187304
.
[28]
Sahni J ， Patel SS ， Dugel PU ，et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema：BOULEVARD phase 2 randomized trial[J]. Ophthalmology， 2019，126(8)∶1155－1170. DOI：
10.1016/j.ophtha.2019.03.023
.
[29]
Wu H ， Hwang DK ， Song X ，et al. Association between aqueous cytokines and diabetic retinopathy stage[J/OL]. J Ophthalmol， 2017，2017∶9402198[2024－01－22]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478856/. DOI：
10.1155/2017/9402198
.
[30]
Feng S ， Yu H ， Yu Y ，et al. Levels of inflammatory cytokines IL-1β，IL-6，IL-8，IL-17A，and TNF-α in aqueous humour of patients with diabetic retinopathy[J/OL]. J Diabetes Res， 2018，2018∶8546423[2024－01－22]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904804/. DOI：
10.1155/2018/8546423
.
[31]
Boss JD ， Singh PK ， Pandya HK ，et al. Assessment of neurotrophins and inflammatory mediators in vitreous of patients with diabetic retinopathy[J]. Invest Ophthalmol Vis Sci， 2017，58(12)∶5594－5603. DOI：
10.1167/iovs.17-21973
.
[32]
Loukovaara S ， Piippo N ， Kinnunen K ，et al. NLRP3 inflammasome activation is associated with proliferative diabetic retinopathy[J]. Acta Ophthalmol， 2017，95(8)∶803－808. DOI：
10.1111/aos.13427
.
[33]
Gao X ， Li Y ， Wang H ，et al. Inhibition of HIF-1α decreases expression of pro-inflammatory IL-6 and TNF-α in diabetic retinopathy[J/OL]. Acta Ophthalmol， 2017，95(8)∶e746－e750[2024－01－22]. https://pubmed.ncbi.nlm.nih.gov/27288252/. DOI：
10.1111/aos.13096
.
[34]
Shirasawa M ， Sonoda S ， Terasaki H ，et al. TNF-α disrupts morphologic and functional barrier properties of polarized retinal pigment epithelium[J]. Exp Eye Res， 2013，110∶59－69. DOI：
10.1016/j.exer.2013.02.012
.
[35]
Behl Y ， Krothapalli P ， Desta T ，et al. Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy[J]. Am J Pathol， 2008，172(5)∶1411－1418. DOI：
10.2353/ajpath.2008.071070
.
[36]
Tsilimbaris MK ， Panagiotoglou TD ， Charisis SK ，et al. The use of intravitreal etanercept in diabetic macular oedema[J]. Semin Ophthalmol， 2007，22(2)∶75－79. DOI：
10.1080/08820530701418243
.
[37]
Hillier RJ ， Ojaimi E ， Wong DT ，et al. Aqueous humor cytokine levels as biomarkers of disease severity in diabetic macular edema[J]. Retina， 2017，37(4)∶761－769. DOI：
10.1097/IAE.0000000000001210
.
[38]
Adamiec-Mroczek J ， Oficjalska-Młyńczak J ．Assessment of selected adhesion molecule and proinflammatory cytokine levels in the vitreous body of patients with type 2 diabetes—role of the inflammatory-immune process in the pathogenesis of proliferative diabetic retinopathy[J]. Graefes Arch Clin Exp Ophthalmol， 2008，246(12)∶1665－1670. DOI：
10.1007/s00417-008-0868-6
.
[39]
Liu K ， Liu H ， Zhang Z ，et al. The role of N-glycosylation in high glucose-induced upregulation of intercellular adhesion molecule-1 on bovine retinal endothelial cells[J]. Acta Ophthalmol， 2016，94(4)∶353－357. DOI：
10.1111/aos.13028
.
[40]
Tamhane M ， Cabrera-Ghayouri S ， Abelian G ，et al. Review of biomarkers in ocular matrices：challenges and opportunities[J/OL]. Pharm Res， 2019，36(3)∶40[2024－01－22]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344398/. DOI：
10.1007/s11095-019-2569-8
.
[41]
Hernández C ， Burgos R ， Cantón A ，et al. Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy：a case-control study[J]. Diabetes Care， 2001，24(3)∶516－521. DOI：
10.2337/diacare.24.3.516
.
[42]
Oh IK ， Kim SW ， Oh J ，et al. Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy[J]. Curr Eye Res， 2010，35(12)∶1116－1127. DOI：
10.3109/02713683.2010.510257
.
[43]
Yu Y ， Zhang J ， Zhu R ，et al. The profile of angiogenic factors in vitreous humor of the patients with proliferative diabetic retinopathy[J]. Curr Mol Med， 2017，17(4)∶280－286. DOI：
10.2174/1566524017666171106111440
.
[44]
Goumans MJ ， Valdimarsdottir G ， Itoh S ，et al. Balancing the activation state of the endothelium via two distinct TGF-beta type Ⅰ receptors[J]. EMBO J， 2002，21(7)∶1743－1753. DOI：
10.1093/emboj/21.7.1743
.
[45]
Khuu LA ， Tayyari F ， Sivak JM ，et al. Aqueous humour concentrations of TGF-β，PLGF and FGF-1 and total retinal blood flow in patients with early non-proliferative diabetic retinopathy[J/OL]. Acta Ophthalmol， 2017，95(3)∶e206－e211[2024－01－22]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5373930/. DOI：
10.1111/aos.13230
.
[46]
Yamamoto N ， Itonaga K ， Marunouchi T ，et al. Concentration of transforming growth factor beta2 in aqueous humor[J]. Ophthalmic Res， 2005，37(1)∶29－33. DOI：
10.1159/000083019
.
[47]
Kowluru RA ， Odenbach S ．Role of interleukin-1beta in the pathogenesis of diabetic retinopathy[J]. Br J Ophthalmol， 2004，88(10)∶1343－1347. DOI：
10.1136/bjo.2003.038133
.
[48]
Carmi Y ， Dotan S ， Rider P ，et al. The role of IL-1β in the early tumor cell-induced angiogenic response[J]. J Immunol， 2013，190(7)∶3500－3509. DOI：
10.4049/jimmunol.1202769
.
[49]
Mao C ， Yan H ．Roles of elevated intravitreal IL-1β and IL-10 levels in proliferative diabetic retinopathy[J]. Indian J Ophthalmol， 2014，62(6)∶699－701. DOI：
10.4103/0301-4738.136220
.
[50]
Stahel M ， Becker M ， Graf N ，et al. Systemic interleukin 1β inhibition in proliferative diabetic retinopathy：a prospective open-label study using canakinumab[J]. Retina， 2016，36(2)∶385－391. DOI：
10.1097/IAE.0000000000000701
.
[51]
Chen H ， Zhang X ， Liao N ，et al. Assessment of biomarkers using multiplex assays in aqueous humor of patients with diabetic retinopathy[J/OL]. BMC Ophthalmol， 2017，17(1)∶176[2024－01－23]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625688/. DOI：
10.1186/s12886-017-0572-6
.
[52]
Bozkurt E ， Çakır B ， Çelik E ，et al. Correlation of the aqueous humor total antioxidant capacity，total oxidant status，and levels of IL-6 and VEGF with diabetic retinopathy status[J]. Arq Bras Oftalmol， 2019，82(2)∶136－140. DOI：
10.5935/0004-2749.20190021
.
[53]
Mocan MC ， Kadayifcilar S ， Eldem B ．Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy[J]. Can J Ophthalmol， 2006，41(6)∶747－752. DOI：
10.3129/i06-070
.
[54]
Coughlin BA ， Trombley BT ， Mohr S ．Interleukin-6 (IL-6) mediates protection against glucose toxicity in human Müller cells via activation of VEGF-A signaling[J]. Biochem Biophys Res Commun， 2019，517(2)∶227－232. DOI：
10.1016/j.bbrc.2019.07.044
.
[55]
Koskela UE ， Kuusisto SM ， Nissinen AE ，et al. High vitreous concentration of IL-6 and IL-8，but not of adhesion molecules in relation to plasma concentrations in proliferative diabetic retinopathy[J]. Ophthalmic Res， 2013，49(2)∶108－114. DOI：
10.1159/000342977
.
[56]
Katagiri M ， Shoji J ， Inada N ，et al. Evaluation of vitreous levels of advanced glycation end products and angiogenic factors as biomarkers for severity of diabetic retinopathy[J]. Int Ophthalmol， 2018，38(2)∶607－615. DOI：
10.1007/s10792-017-0499-1
.
[57]
Yenihayat F ， Özkan B ， Kasap M ，et al. Vitreous IL-8 and VEGF levels in diabetic macular edema with or without subretinal fluid[J]. Int Ophthalmol， 2019，39(4)∶821－828. DOI：
10.1007/s10792-018-0874-6
.
[58]
Schoenberger SD ， Kim SJ ， Shah R ，et al. Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac，0.45%，in patients with diabetic retinopathy[J]. JAMA Ophthalmol， 2014，132(1)∶32－37. DOI：
10.1001/jamaophthalmol.2013.6203
.
[59]
Takeuchi M ， Sato T ， Tanaka A ，et al. Elevated levels of cytokines associated with Th2 and Th17 cells in vitreous fluid of proliferative diabetic retinopathy patients[J/OL]. PLoS One， 2015，10(9)∶e0137358[2024－01－23]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4564282/. DOI：
10.1371/journal.pone.0137358
.
[60]
Wang Y ， Fan L ， Meng X ，et al. Transplantation of IL-10-transfected endothelial progenitor cells improves retinal vascular repair via suppressing inflammation in diabetic rats[J]. Graefes Arch Clin Exp Ophthalmol， 2016，254(10)∶1957－1965. DOI：
10.1007/s00417-016-3427-6
.
[61]
Udaondo P ， Hernández C ， Briansó-Llort L ，et al. Usefulness of liquid biopsy biomarkers from aqueous humor in predicting anti-VEGF response in diabetic macular edema：results of a pilot study[J/OL]. J Clin Med， 2019，8(11)∶1841[2024－01－23]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912573/. DOI：
10.3390/jcm8111841
.
[62]
Felfeli T ， Juncal VR ， Hillier RJ ，et al. Aqueous humor cytokines and long-term response to anti-vascular endothelial growth factor therapy in diabetic macular edema[J]. Am J Ophthalmol， 2019，206∶176－183. DOI：
10.1016/j.ajo.2019.04.002
.
[63]
Wei Q ， Wan Z ， Hu Y ，et al. Cytokine and chemokine profile changes in patients after intravitreal conbercept injection for diabetic macular edema[J]. Drug Des Devel Ther， 2019，13∶4367－4374. DOI：
10.2147/DDDT.S222004
.
[64]
Zhou J ， Liu Z ， Chen M ，et al. Concentrations of VEGF and PIGF decrease in eyes after intravitreal conbercept injection[J]. Diabetes Ther， 2018，9(6)∶2393－2398. DOI：
10.1007/s13300-018-0527-9
.
[65]
Mastropasqua R ， D'Aloisio R ， Di Nicola M ，et al. Relationship between aqueous humor cytokine level changes and retinal vascular changes after intravitreal aflibercept for diabetic macular edema[J/OL]. Sci Rep， 2018，8(1)∶16548[2024－01－23]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224583/. DOI：
10.1038/s41598-018-35036-9
.
[66]
Hillier RJ ， Ojaimi E ， Wong DT ，et al. Aqueous humor cytokine levels and anatomic response to intravitreal ranibizumab in diabetic macular edema[J]. JAMA Ophthalmol， 2018，136(4)∶382－388. DOI：
10.1001/jamaophthalmol.2018.0179
.
[67]
Figueras-Roca M ， Sala-Puigdollers A ， Alforja S ，et al. Aqueous humour cytokine changes with intravitreal dexamethasone implant injection for diabetic macular edema[J]. Ocul Immunol Inflamm， 2019，27(8)∶1203－1210. DOI：
10.1080/09273948.2019.1636095
.
[68]
Choi MY ， Jee D ， Kwon JW . Characteristics of diabetic macular edema patients refractory to anti-VEGF treatments and a dexamethasone implant[J/OL]. PLoS One， 2019，14(9)∶e0222364[2024－01－23]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742354/. DOI：
10.1371/journal.pone.0222364
.
[69]
Yu SY ， Nam DH ， Lee DY . Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema[J]. Graefes Arch Clin Exp Ophthalmol， 2018，256(1)∶39－47. DOI：
10.1007/s00417-017-3819-2
.
[70]
Midena E ， Micera A ， Frizziero L ，et al. Sub-threshold micropulse laser treatment reduces inflammatory biomarkers in aqueous humour of diabetic patients with macular edema[J/OL]. Sci Rep， 2019，9(1)∶10034[2024－01－23]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624368/. DOI：
10.1038/s41598-019-46515-y
.
[71]
Midena E ， Bini S ， Frizziero L ，et al. Aqueous humour concentrations of PEDF and erythropoietin are not influenced by subthreshold micropulse laser treatment of diabetic macular edema[J/OL]. Biosci Rep， 2019，39(6)∶BSR20190328[2024－01－23]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6579974/. DOI：
10.1042/BSR20190328
.
[72]
Li B ， Li MD ， Ye JJ ，et al. Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy[J]. Chin Med J (Engl)， 2020，133(6)∶664－669. DOI：
10.1097/CM9.0000000000000687
.
[73]
Van Geest RJ ， Lesnik-Oberstein SY ， Tan HS ，et al. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy[J]. Br J Ophthalmol， 2012，96(4)∶587－590. DOI：
10.1136/bjophthalmol-2011-301005
.
[74]
Yan Y ， Zhu L ， Hong L ，et al. The impact of ranibizumab on the level of intercellular adhesion molecule type 1 in the vitreous of eyes with proliferative diabetic retinopathy[J]. Acta Ophthalmol， 2016，94(4)∶358－364. DOI：
10.1111/aos.12806
.
[75]
Raczyńska D ， Lisowska KA ， Pietruczuk K ，et al. The level of cytokines in the vitreous body of severe proliferative diabetic retinopathy patients undergoing posterior vitrectomy[J]. Curr Pharm Des， 2018，24(27)∶3276－3281. DOI：
10.2174/1381612824666180926110704
.
[76]
Shimura M ， Yasuda K ， Nakazawa T ，et al. Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy[J]. Graefes Arch Clin Exp Ophthalmol， 2009，247(12)∶1617－1624. DOI：
10.1007/s00417-009-1147-x
.
[77]
Shimura M ， Yasuda K ， Nakazawa T ，et al. Panretinal-photocoagulation before pars plana vitrectomy influences vitreous level of interleukin-6 but not of vascular endothelial growth factor in patients with diabetic retinopathy[J]. Int J Biomed Sci， 2007，3(1)∶31－37.
[78]
Sánchez MC ， Luna JD ， Barcelona PF ，et al. Effect of retinal laser photocoagulation on the activity of metalloproteinases and the alpha(2)-macroglobulin proteolytic state in the vitreous of eyes with proliferative diabetic retinopathy[J]. Exp Eye Res， 2007，85(5)∶644－650. DOI：
10.1016/j.exer.2007.07.018
.
[79]
Itakura H ， Kishi S ， Kotajima N ，et al. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy[J]. Ophthalmology， 2004，111(10)∶1880－1884. DOI：
10.1016/j.ophtha.2004.03.035
.
[80]
Yoshida S ， Kobayashi Y ， Nakao S ，et al. Differential association of elevated inflammatory cytokines with postoperative fibrous proliferation and neovascularization after unsuccessful vitrectomy in eyes with proliferative diabetic retinopathy[J]. Clin Ophthalmol， 2017，11∶1697－1705. DOI：
10.2147/OPTH.S141821
.
[81]
Wang T ， Li J ， Xie R ，et al. Intraocular tumour necrosis factor ligand related molecule 1 A links disease progression of proliferative diabetic retinopathy after primary vitrectomy[J]. Clin Exp Pharmacol Physiol， 2020，47(6)∶966－976. DOI：
10.1111/1440-1681.13284
.
[82]
Yoshida S ， Kubo Y ， Kobayashi Y ，et al. Increased vitreous concentrations of MCP-1 and IL-6 after vitrectomy in patients with proliferative diabetic retinopathy：possible association with postoperative macular oedema[J]. Br J Ophthalmol， 2015，99(7)∶960－966. DOI：
10.1136/bjophthalmol-2014-306366
.
备注信息
评论 （0条）
注册 登录
时间排序
- 时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
新生血管性青光眼患者眼内液中细胞因子表达的meta分析
朱树青 等 中华实验眼科杂志 2024,42(06)
眼内液细胞因子检测在糖尿病黄斑水肿中临床意义的研究进展
曾国强 等 中华眼底病杂志 2024,40(08)
不同程度DR对三维脉络膜血管指数变化的影响及其意义
纪风涛 等 中华实验眼科杂志 2024,42(08)
中国2型糖尿病防治指南（2020年版）
中华医学会糖尿病学分会 中华糖尿病杂志 2021,13(04)
分享
详细信息
表
访问与引文
阅读权限
参考文献
访问与引用
访问数据
0
0
全部时间 最近30天 最近6个月 最近12个月
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照
文献快照
N/A
N/A
AI总结中
N/A
N/A
快照内容由人工智能生成，供您参考。
你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。
0/50
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
0/2000
信息反馈
中文(简体)
英文
翻译
机器翻译功能由科大讯飞提供技术支持
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
你好！ 今天我能为您提供什么帮助？
0/30
of
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
扩写 缩写 改写 翻译
0/2000
信息反馈
历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大
翻译
润色
扩写
缩写
复制
引用
